Interferon-β suppresses murine Th1 cell function in the absence of antigen-presenting cells

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Boivin, Nicolas ^a   Baillargeon, Joanie ^a   Doss, Prenitha Mercy Ignatius Arokia ^a,b   Roy, Andrée Pascale ^a,b   Rangachari, Manu ^a,b  

^a University Laval   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON; BETA INTERFERON RECEPTOR; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 27; L SELECTIN; RECEPTOR; REGULATORY RECEPTOR T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN CONTAINING 3; STAT1 PROTEIN; STAT4 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CELL TRANSFER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOWN REGULATION; DRUG MECHANISM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNOMODULATION; IN VITRO STUDY; INTRACELLULAR SIGNALING; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAG1-/- MOUSE; TH1 CELL; UPREGULATION; ANIMAL; C57BL MOUSE; IMMUNOLOGY; PHYSIOLOGY;

MURINAE; MUS;

ANIMALS; ANTIGEN-PRESENTING CELLS; INTERFERON-BETA; MICE; MICE, INBRED C57BL; TH1 CELLS;

EID: 84929485396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124802     Document Type: Article

References (77)

1. Beck CA, Metz LM, Svenson LW, Patten SB. Regional variation of multiple sclerosis prevalence in Canada. Mult Scler. 2005; 11: 516-519. PMID: 16193887
2. Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother. 2013; 13: 3-9. doi: 10.1586/14737175.2013.865866 PMID: 24289836
3. Nyland H, Mörk S, Matre R. In-situ characterization of mononuclear cell infiltrates in lesions of multiple sclerosis. Neuropathol Appl Neurobiol. 1982; 8: 403-411. PMID: 6983662
4. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NS, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011; 476: 214-219. doi: 10.1038/nature10251 PMID: 21833088
5. Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics. 2007; 4: 647-653. doi: 10.1016/j.nurt.2007.08.002 PMID: 17920545
6. Clerico M, Contessa G, Durelli L. Interferon-beta1a for the treatment of multiple sclerosis. Expert Opin Biol Ther. 2007; 7: 535-542. doi: 10.1517/14712598.7.4.535 PMID: 17373904
7. Rangachari M, Kuchroo VK. Using EAE to better understand principles of immune function and autoimmune pathology. J Autoimmun. 2013; 45: 31-39. doi: 10.1016/j.jaut.2013.06.008 PMID: 23849779
8. El-behi M, Rostami A, Ciric B. Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. 2010; 5: 189-197. doi: 10.1007/s11481-009-9188-9 PMID: 20107924
9. Petermann F, Korn T. Cytokines and effector T cell subsets causing autoimmune CNS disease. FEBS Lett. 2011; 585: 3747-3757. doi: 10.1016/j.febslet.2011.03.064 PMID: 21477588
10. Burks J. Interferon-beta1b for multiple sclerosis. Expert Rev Neurother. 2005; 5: 153-164. doi: 10.1586/14737175.5.2.153 PMID: 15853486
11. Prinz M, Schmidt H, Mildner A, Knobeloch K-P, Hanisch U-K, Raasch J, et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity. 2008; 28: 675-686. doi: 10.1016/j.immuni.2008.03.011 PMID: 18424188
12. Sweeney CM, Lonergan R, Basdeo SA, Kinsella K, Dungan LS, Higgins SC, et al. IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav Immun. 2011; 25: 1170-1181. doi: 10.1016/j.bbi.2011.03.007 PMID: 21420486
13. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest. 2008; 118: 1680-1690. doi: 10.1172/JCI33342 PMID: 18382764
14. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol. 1993; 46: 145-153. PMID: 8360326
15. Brod SA, Nelson LD, Khan M, Wolinsky JS. IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months. Int J Neurosci. 1997; 90: 135-144. PMID: 9285295
16. Yang L, Anderson DE, Kuchroo J, Hafler DA. Lack of TIM-3 immunoregulation in multiple sclerosis. J Immunol. 2008; 180: 4409-4414. PMID: 18354161
17. Luca ME, Visser L, Lucas CJ, Nagelkerken L. IFN-beta modulates specific T cell responses in vitro but does not affect Experimental Autoimmune Encephalomyelitis in the SJL mouse. J Neuroimmunol. 1999; 100: 190-196. PMID: 10695729
18. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med. 2010; 16: 406-412. doi: 10.1038/nm.2110 PMID: 20348925
19. McRae BL, Picker LJ, van Seventer GA. Human recombinant interferon-beta influences T helper subset differentiation by regulating cytokine secretion pattern and expression of homing receptors. Eur J Immunol. 1997; 27: 2650-2656. doi: 10.1002/eji.1830271026 PMID: 9368622
20. Lombardi G, Dunne PJ, Scheel-Toellner D, Sanyal T, Pilling D, Taams LS, et al. Type 1 IFN maintains the survival of anergic CD4+ T cells. J Immunol. 2000; 165: 3782-3789. PMID: 11034383
21. Huber JP, Farrar JD. Regulation of effector and memory T-cell functions by type I interferon. Immunology. 2011; 132: 466-474. doi: 10.1111/j.1365-2567.2011.03412.x PMID: 21320124
22. Ramgolam VS, Sha Y, Jin J, Zhang X, Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. J Immunol. 2009; 183: 5418-5427. doi: 10.4049/jimmunol.0803227 PMID: 19783688
23. Pennell LM, Fish EN. Immunoregulatory Effects of Interferon-β in Suppression of Th17 cells. J Interferon Cytokine Res. 2014; 34: 330-41. doi: 10.1089/jir.2013.0088 PMID: 24175628
24. Shinohara ML, Kim J-H, Garcia VA, Cantor H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity. 2008; 29: 68-78. doi: 10.1016/j.immuni.2008.05.008 PMID: 18619869
25. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med. 2008; 197: 1073-1081. doi: 10.1084/jem.20021603
26. Rangachari M, Zhu C, Sakuishi K, Xiao S, Karman J, Chen A, et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat Med. 2012; 18: 1394-1400. doi: 10.1038/nm.2871 PMID: 22863785
27. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sánchez-Fueyo A, Zheng XX, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003; 4: 1102-1110. doi: 10.1038/ni988 PMID: 14556006
28. Starossom SC, Mascanfroni ID, Imitola J, Cao L, Raddassi K, Hernandez SF, et al. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity. 2012; 37: 249-263. doi: 10.1016/j.immuni.2012.05.023 PMID: 22884314
29. Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton SE, Franz B, et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity. 2011; 35: 986-996. doi: 10.1016/j.immuni.2011.10.015 PMID: 22177922
30. Müller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994; 264: 1918-1921. PMID: 8009221
31. Shata MT, Faltynek CR, Lewis GK, Kamin-Lewis RM. Absence of high-affinity binding sites for interferon alpha/beta in variant murine CD4+ T lymphocytes not expressing the T cell antigen receptor. J Interferon Cytokine Res. 1995; 15: 291-296. PMID: 7627803
32. McRae BL, Semnani RT, Hayes MP, van Seventer GA. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J Immunol. 1998; 160: 4298-4304. PMID: 9574532
33. Rep MH, Hintzen RQ, Polman CH, van Lier RA. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol. 1996; 67: 111-118. PMID: 8765333
34. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441: 235-238. doi: 10.1038/nature04753 PMID: 16648838
35. Jäger A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol. 2009; 183: 7169-7177. doi: 10.4049/jimmunol.0901906 PMID: 19890056
36. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002; 415: 536-541. doi: 10.1038/415536a PMID: 11823861
37. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6: 1245-1252. doi: 10.1038/ni1271 PMID: 16286920
38. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010; 207: 2187-2194. doi: 10.1084/jem.20100643 PMID: 20819927
39. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008; 205: 2763-2779. doi: 10.1084/jem.20081398 PMID: 19001139
40. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000; 100: 655-669. PMID: 10761931
41. Anderson AC, Lord GM, Dardalhon V, Lee DH, Sabatos-Peyton CA, Glimcher LH, et al. T-bet, a Th1 transcription factor regulates the expression of Tim-3. Eur J Immunol. 2010; 40: 859-866. doi: 10.1002/eji.200939842 PMID: 20049876
42. Agnello D, Lankford CSR, Bream J, Morinobu A, Gadina M, O'Shea JJ, et al. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol. 2003; 23: 147-161. PMID: 12797537
43. Kimura A, Naka T, Kishimoto T. IL-6-dependent and-independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci USA. 2007; 104: 12099-12104. doi: 10.1073/pnas.0705268104 PMID: 17623780
44. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012; 135: 44-53. doi: 10.1016/j.pharmthera.2012.03.006 PMID: 22484806
45. Avolio C, Giuliani F, Liuzzi GM, Ruggieri M, Paolicelli D, Riccio P, et al. Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta. Brain Res Bull. 2003; 61: 357-364. PMID: 12909305
46. Jacobs L, Johnson KP. A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol. 1994; 51: 1245-1252. PMID: 7986181
47. Pozzilli C, Prosperini L, Sbardella E, Paolillo A. Interferon after 10 years in patients with multiple sclerosis. Neurol Sci. 2006; 27 Suppl 5: S369-S372. doi: 10.1007/s10072-006-0697-5 PMID: 16998723
48. Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol. 2006; 59: 344-352. doi: 10.1002/ana.20740 PMID: 16437558
49. Polman CH, Uitdehaag BMJ. New and emerging treatment options for multiple sclerosis. Lancet Neurol. 2003; 2: 563-566. PMID: 12941579
50. Melo A, Rodrigues B, Bar-Or A. Beta interferons in clinically isolated syndromes: a meta-analysis. Arq Neuropsiquiatr. 2008; 66: 8-10. PMID: 18392405
51. Axtell RC, Raman C, Steinman L. Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity. Clin Rev Allergy Immunol. 2013; 44: 114-120. doi: 10.1007/s12016-011-8296-5 PMID: 22231516
52. Rudick RA, Rani MRS, Xu Y, Lee J-C, Na J, Schrock J, et al. Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis. PLoS ONE. 2011; 6: e19262. doi: 10.1371/journal.pone.0019262 PMID: 21602934
53. Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs. 2011; 25: 491-502. doi: 10.2165/11591110-000000000-00000 PMID: 21649449
54. Kraus J, Oschmann P. The impact of interferon-beta treatment on the blood-brain barrier. Drug Discov Today. 2006; 11: 755-762. doi: 10.1016/j.drudis.2006.06.008 PMID: 16846804
55. Zhang J, Hutton G, Zang Y. A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clin Ther. 2002; 24: 1998-2021. PMID: 12581542
56. Inogés S, Merino J, Bandrés E, De Castro P, Subirá ML, Sanchez-Ibarrola A. Cytokine flow cytometry differentiates the clinical status of multiple sclerosis (MS) patients. Clin Exp Immunol. 1999; 115: 521-525. PMID: 10193428
57. Liu Z, Pelfrey CM, Cotleur A, Lee JC, Rudick RA. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol. 2001; 112: 153-162. PMID: 11108944
58. Karp CL, van Boxel-Dezaire AH, Byrnes AA, Nagelkerken L. Interferon-beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10? Curr Opin Neurol. 2001; 14: 361-368. PMID: 11371761
59. Sprent J, Zhang X, Sun S, Tough D. T-cell proliferation in vivo and the role of cytokines. Philos Trans R Soc Lond, B, Biol Sci. 2000; 355: 317-322. doi: 10.1098/rstb.2000.0568 PMID: 10794049
60. Deonarain R, Verma A, Porter ACG, Gewert DR, Platanias LC, Fish EN. Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha. Proc Natl Acad Sci USA. 2003; 100: 13453-13458. doi: 10.1073/pnas.2230460100 PMID: 14597717
61. Veldhoen M, Hocking RJ, Flavell RA, Stockinger B. Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol. 2006; 7: 1151-1156. doi: 10.1038/ni1391 PMID: 16998492
62. Tigno-Aranjuez JT, Jaini R, Tuohy VK, Lehmann PV, Tary-Lehmann M. Encephalitogenicity of complete Freund's adjuvant relative to CpG is linked to induction of Th17 cells. J Immunol. 2009; 183: 5654-5661. doi: 10.4049/jimmunol.0900645 PMID: 19812193
63. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011; 117: 4501-4510. doi: 10.1182/blood-2010-10-310425 PMID: 21385853
64. Jin H-T, Anderson AC, Tan WG, West EE, Ha S-J, Araki K, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA. 2010; 107: 14733-14738. doi: 10.1073/pnas.1009731107 PMID: 20679213
65. Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell. 2009; 138: 30-50. doi: 10.1016/j.cell.2009.06.036 PMID: 19596234
66. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006; 439: 682-687. doi: 10.1038/nature04444 PMID: 16382236
67. McMahan RH, Golden-Mason L, Nishimura MI, McMahon BJ, Kemper M, Allen TM, et al. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest. 2010; 120: 4546-4557. doi: 10.1172/JCI43127 PMID: 21084749
68. Koguchi K, Anderson DE, Yang L, O'Connor KC, Kuchroo VK, Hafler DA. Dysregulated T cell expression of TIM3 in multiple sclerosis. J Exp Med. 2006; 203: 1413-1418. doi: 10.1084/jem.20060210 PMID: 16754722
69. Liu Y, Carlsson R, Comabella M, Wang J, Kosicki M, Carrion B, et al. FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nat Med. 2014; 20: 272-282. doi: 10.1038/nm.3485 PMID: 24531377
70. Visconti R, Gadina M, Chiariello M, Chen EH, Stancato LF, Gutkind JS, et al. Importance of the MKK6/p38 pathway for interleukin-12-induced STAT4 serine phosphorylation and transcriptional activity. Blood. 2000; 96: 1844-1852. PMID: 10961885
71. Chitnis T, Najafian N, Benou C, Salama AD, Grusby MJ, Sayegh MH, et al. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest. 2001; 108: 739-747. doi: 10.1172/JCI12563 PMID: 11544280
72. Kamiya S, Owaki T, Morishima N, Fukai F, Mizuguchi J, Yoshimoto T. An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. J Immunol. 2004; 173: 3871-3877. PMID: 15356135
73. Bettelli E, Sullivan B, Szabo SJ, Sobel RA, Glimcher LH, Kuchroo VK. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med. 2004; 200: 79-87. doi: 10.1084/jem.20031819 PMID: 15238607
74. Usui T, Preiss JC, Kanno Y, Yao ZJ, Bream JH, O'Shea JJ, et al. T-bet regulates Th1 responses through essential effects on GATA-3 function rather than on IFNG gene acetylation and transcription. J Exp Med 2006; 203: 755-766. doi: 10.1084/jem.20052165 PMID: 16520391
75. Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science 2005; 307: 430-433. doi: 10.1126/science.1103336 PMID: 15662016
76. Zhu C, Sakuishi K, Xiao S, Sun Z, Zaghouani S, Gu G, et al. An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nat Commun. 2015; 6: 6072. doi: 10.1038/ncomms7072 PMID: 25614966
77. Arnason BG. Immunologic therapy of multiple sclerosis. Annu Rev Med. 1999; 50: 291-302. doi: 10.1146/annurev.med.50.1.291 PMID: 10073279